| Literature DB >> 16684675 |
H J Chae1, K H Choi, S W Chae, H M Kim, T K Shin, G Y Lee, G S Jeong, H R Park, H I Choi, S B Kim, S K Yoo, H R Kim.
Abstract
In China, Japan, and Korea, placenta hominis extracts (PHEs) are used clinically for the treatment of osteoporosis. The anti-osteoporotic effect of PHEs was studied. The trabecular bone area and thickness in OVX rats decreased by 50% from those in sham-operated rats; these decreases were completely inhibited by administration of PHEs for 7 weeks. Osteoclast numbers and the osteoblast surface were enhanced in OVX rats, but PHEs had no effect on these phenomena. Serum phosphorus and alkaline phosphatase in OVX rats increased compared to those in sham-operated rats, but the increases were not affected by the administration of PHEs. Thyroxine (T4) level was stimulated in OVX rats. The extracts inhibited the T4 level in the OVX rats. These results strongly suggest that PHEs be effective in preventing the development of bone loss induced by OVX in rats.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16684675 DOI： 10.1080/08923970600626197
Source DB: PubMed Journal: Immunopharmacol Immunotoxicol ISSN： 0892-3973 Impact factor: 2.730